
Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations, expanding the addressable patient population by offering one solution for many mutations. Our mission: defeat cancer resistance and provide people living with cancer the opportunity to experience longer, healthier and more active lives. We are advancing two potent, brain-penetrant clinical-stage programs: BDTX-1535, a fourth-generation EGFR inhibitor targeting non-small cell lung cancer (NSCLC) and glioblastoma (GBM) and BDTX-4933, a RAF inhibitor targeting KRAS, NRAS and BRAF alterations in NSCLC and other solid tumors.
Up to 90% verified emails and mobile numbers, refreshed weekly.
Black Diamond Therapeutics operates in the Biotechnology Research industry and is headquartered in United States.
Black Diamond Therapeutics has approximately 51-200 employees employees.
Black Diamond Therapeutics is based in Cambridge, MA, United States.
Yes. Black Diamond Therapeutics is a publicly traded company.
You can reach Black Diamond Therapeutics’s investor relations department through the contact section on their official website or directly via the investor relations email listed in their latest SEC filings.
Up to 90% verified emails and mobile numbers, backed by weekly job-change alerts.
An email pattern tells you the format. It does not tell you who works there now or whether an address still delivers. Scalelist returns verified contacts, checked at the point you build the list.
Our team will be in touch soon. If you have any questions, please email us at info@scalelist.com
Just a few more details..
Our team will be in touch soon. If you have any questions, please email us at arnaud@scalelist.com